Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Tarsus Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 78.19 · gapped above the open, then crossed back over prior close. High/low 80.44 at 4:45 am ET, 78.08 at 1:45 pm ET.
Tarsus Pharmaceuticals, Inc. has 6 disclosed suppliers and 4 disclosed customers. Each one is named in an SEC filing, either Tarsus Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In September 2020, we entered into a license agreement with Elanco granting us a worldwide license to certain intellectual property for the development and commercialization of lotilaner for the treatment, palliation, prevention or cure of all other diseases and conditions in humans (i.e., beyond that of the eye or skin), as amended in June 2022 (the "All Human Uses Elanco Agreement").”
FILING10-K0001819790-26-000019cik 0001819790
“Under the terms of the 2023 ATM Prospectus and ATM Sales Agreement, Jefferies will act as the Company's sales agent and is entitled to compensation for its services equal to 3% of the gross proceeds of any shares of common stock sold.”
FILING10-K0001819790-26-000019cik 0001819790
“In April 2024, we executed the 2024 Credit Facility with Pharmakon with maturity in April 2029.”
FILING10-K0001819790-26-000019cik 0001819790
“Through December 31, 2025, we received aggregate payments from LianBio totaling $86.1 million comprised of: (i) $15.0 million of initial consideration; (ii) $67.5 million for the achievement of specified milestones; (iii) $2.5 million upon execution of the Novation Agreement; (iv) $0.4 million upon execution of the Warrant Termination Agreement; and (v) $0.7 million related to a special cash dividend.”
FILING10-K0001819790-26-000019cik 0001819790
“As of December 31, 2025, we are eligible to receive further consideration from GrandPharma upon the achievement of additional TP-03 events, including: (i) additional regulatory and/or patent issuance milestones of up to an aggregate of $20.0 million; (ii) China-based TP-03 sales threshold milestone payments of up to an aggregate of $100.0 million and (iii) tiered low-to-high-teen royalties for China Territory TP-03 product sales.”
FILING10-K0001819790-26-000019cik 0001819790
“The terms of our Eye and Derm Elanco Agreement, All Human Uses Elanco Agreement, Other In-License Agreement, and February 2026 In-License Agreement require us to make future development milestone payments aggregating up to $11.5 million and future commercial and sales-based milestone payments aggregating up to $341.0 million upon our achievement of the specified milestones.”
FILING10-K0001819790-26-000019cik 0001819790
“To date, we have financed our operations through private placements of preferred stock, convertible promissory notes, net proceeds from issuance of common stock in our initial public offering ("IPO"), our subsequent follow-on public offerings in May 2022 (the "May 2022 Public Offering"), August 2023 (the "August 2023 Public Offering"), March 2024 (the "March 2024 Public Offering"), and March 2025 (the "March 2025 Public Offering", collectively the "Follow-On Public Offerings"), and our Open Market Sale Agreement TM (the "2023 ATM Prospectus"), as well as proceeds from net product sales, our China Out-License, and drawdowns from the loan and security agreement (the "2024 Credit Facility") with funds associated with Pharmakon Advisors, LP ("Pharmakon"), and the previous loan and security agreement with Hercules Capital, Inc. and Silicon Valley Bank, a division of First Citizens Bank & Trust Company (the "2022 Credit Facility", and collectively the "Credit Facilities").”
FILING10-K0001819790-26-000019cik 0001819790
“To date, we have financed our operations through private placements of preferred stock, convertible promissory notes, net proceeds from issuance of common stock in our initial public offering ("IPO"), our subsequent follow-on public offerings in May 2022 (the "May 2022 Public Offering"), August 2023 (the "August 2023 Public Offering"), March 2024 (the "March 2024 Public Offering"), and March 2025 (the "March 2025 Public Offering", collectively the "Follow-On Public Offerings"), and our Open Market Sale Agreement TM (the "2023 ATM Prospectus"), as well as proceeds from net product sales, our China Out-License, and drawdowns from the loan and security agreement (the "2024 Credit Facility") with funds associated with Pharmakon Advisors, LP ("Pharmakon"), and the previous loan and security agreement with Hercules Capital, Inc. and Silicon Valley Bank, a division of First Citizens Bank & Trust Company (the "2022 Credit Facility", and collectively the "Credit Facilities").”
FILING10-K0001819790-26-000019cik 0001819790
“In March 2024, we executed the Novation Agreement with GrandPharma and LianBio to transition the rights to develop and commercialize TP-03 in China for the treatment of Demodex blepharitis and MGD.”
FILING10-K0001819790-26-000019cik 0001819790
“In March 2024, we executed the Novation Agreement with GrandPharma and LianBio to transition the rights to develop and commercialize TP-03 in China for the treatment of Demodex blepharitis and MGD.”
FILING10-K0001819790-26-000019cik 0001819790
Watchlist prices, news filtered to it, and its next report on your desk.
TARS (Tarsus Pharmaceuticals, Inc.) has 6 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ELAN −0.65%, in healthcare.